Early trial tests common bone drug against rare bone cancer
NCT ID NCT03173976
Summary
This early-stage study is testing whether a drug called zoledronic acid, commonly used to strengthen bones, can help control tumor growth in patients with a rare bone cancer called chondrosarcoma. The drug is given once before surgery and once after, and researchers are checking if it's safe and if it affects the tumor. The main goal is to see if this approach can help prevent the cancer from coming back after surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHONDROSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.